Oxytocin and Cognitive Control in Adult ADHD
| Status: | Recruiting |
|---|---|
| Conditions: | Neurology, Psychiatric |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 3/3/2019 |
| Start Date: | December 14, 2017 |
| End Date: | June 2019 |
| Contact: | Franziska Plessow, Ph.D. |
| Email: | fplessow@mgh.harvard.edu |
| Phone: | 617-726-0784 |
Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity Disorder
This is a randomized, double-blind, placebo-controlled crossover study of single-dose
intranasal oxytocin (24 IU) in 18-55 year-old men with attention deficit/hyperactivity
disorder (ADHD). Following a screening visit to determine eligibility, participants will
return for two main study visits. During the main study visits, study participants will
receive either oxytocin (Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland) or
placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy), followed by
assessments of cognitive control over attention and behavior. Twenty-four participants will
be randomized 1:1 to one of two drug orders, i.e., oxytocin - placebo or placebo - oxytocin.
In an additional neuroimaging substudy, a subset of participants will undergo task-based and
resting-state functional magnetic resonance imaging (fMRI) following oxytocin/placebo
administration to investigate the effects of oxytocin on fMRI activation and functional
connectivity within the cognitive control network.
intranasal oxytocin (24 IU) in 18-55 year-old men with attention deficit/hyperactivity
disorder (ADHD). Following a screening visit to determine eligibility, participants will
return for two main study visits. During the main study visits, study participants will
receive either oxytocin (Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland) or
placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy), followed by
assessments of cognitive control over attention and behavior. Twenty-four participants will
be randomized 1:1 to one of two drug orders, i.e., oxytocin - placebo or placebo - oxytocin.
In an additional neuroimaging substudy, a subset of participants will undergo task-based and
resting-state functional magnetic resonance imaging (fMRI) following oxytocin/placebo
administration to investigate the effects of oxytocin on fMRI activation and functional
connectivity within the cognitive control network.
Inclusion criteria:
- Male
- 18-55 years
- Diagnosis of attention deficit/hyperactivity disorder
Exclusion criteria:
- History of cardiovascular disease (e.g., hypertrophic cardiomyopathy, valvular heart
disease, coronary heart disease, or coronary artery spasms)
- History of diabetes mellitus
- Untreated thyroid disease
- Hematocrit below the normal range
- Tobacco use
- Any other significant illness or condition that the investigator determines could
interfere with study participation or safety or put the subject at any unnecessary
risk
We found this trial at
1
site
Click here to add this to my saved trials
